Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Mineralys Therapeutics (MLYS) reported Q2 2025 results, ending with $324.9 million in cash and investments as of June 30, 2025, providing a runway into 2027, despite a net loss of $43.3 million for the quarter. The company highlighted significant clinical progress for its lead aldosterone synthase inhibitor, lorundrostat, with positive pivotal data from Launch-HTN and Advance-HTN trials demonstrating clinically meaningful blood pressure reductions in uncontrolled and resistant hypertension, supported by high physician intent to prescribe and a large market opportunity. Further positive results were noted from the Explore-CKD trial, while the Explore-OSA trial's top-line data is anticipated in Q1 2026. Mineralys is preparing for a Q4 2025 pre-NDA meeting with the FDA, expressing confidence in lorundrostat's differentiated efficacy and safety profile, and is actively pursuing partnerships to maximize market reach.

Analysis

Mineralys Therapeutics (MLYS) presented a confident outlook during its Q2 2025 earnings call, underpinned by a strong cash position of $324.9 million, providing a funding runway into 2027. The company is advancing its lead aldosterone synthase inhibitor, lorundrostat, toward regulatory submission following positive pivotal data from the Launch-HTN and Advance-HTN trials, which demonstrated significant reductions in systolic blood pressure and have been published in major medical journals. This clinical success is bolstered by market research indicating high physician adoption potential, with a survey showing 95% of clinicians would likely prescribe the drug in third-line or later hypertension, a market segment IQVIA data suggests involves nearly 9 million patients annually in the U.S. The drug's profile is further enhanced by positive results in comorbid conditions; the Explore-CKD trial showed a meaningful blood pressure reduction and a significant decrease in UACR in patients already on SGLT2 inhibitors. Key upcoming catalysts include a pre-NDA meeting with the FDA scheduled for Q4 2025 and top-line data from the EXPLORE-OSA trial in Q1 2026. While management is actively pursuing partnerships to maximize commercial reach, it must also navigate the competitive landscape, with AstraZeneca's rival ASI, baxdrostat, expected to report Phase III data shortly. Management addressed this by highlighting lorundrostat’s distinct pharmacokinetic profile, specifically its 10-12 hour half-life, and expressed confidence in its comprehensive data package.

Key Decisions for Investors

• Investors should monitor the outcome of the pre-NDA meeting with the FDA in Q4 2025 and any subsequent partnership announcements, as these are critical near-term catalysts for de-risking the asset and unlocking value.
• Closely evaluate the upcoming Phase III data for AstraZeneca's competing drug, baxdrostat, paying specific attention to efficacy and hyperkalemia rates, as this will establish the primary competitive benchmark and influence market positioning.
• Consider the company's progress on its commercial strategy, particularly its payer access plan, which aims to secure favorable utilization management criteria by avoiding a step-edit through spironolactone.
• Watch for top-line data from the EXPLORE-OSA trial in Q1 2026, as positive results in this comorbid condition could significantly expand lorundrostat's addressable market and strengthen its value proposition.